Technology
Health
Pharmaceutical

Revance Therapeutics

$15.47
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.49 (-3.07%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell RVNC and other stocks, options, ETFs, and crypto commission-free!

About

Revance Therapeutics, Inc. Common Stock, also called Revance Therapeutics, is a clinical stage biotechnology company. Read More It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.

Employees
170
Headquarters
Newark, California
Founded
1999
Market Cap
572.01M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
329.53K
High Today
$15.98
Low Today
$15.41
Open Price
$15.91
Volume
156.31K
52 Week High
$34.20
52 Week Low
$15.07

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
Manufacturing
2014 IPO

News

MarketBeatMar 8

Stock Price, News, & Analysis for Revance Therapeutics

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001)...

47
Seeking AlphaFeb 26

Revance Therapeutics, Inc. (RVNC) CEO Daniel Browne on Q4 2018 Results - Earnings Call Transcript

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2018 Earnings Conference Call February 26, 2019 4:30 PM ET Company Participants Jeanie Herbert - Senior Director of Investor Relations and Corporate Communications Daniel Browne - President and Chief Executive Officer Tobin Schilke - Chief Financial Officer Abhay Joshi - Chief Operating Officer Dustin Sjuts - Head of Commercial Aesthetics and Therapeutics Conference Call Participants Stacy Ku - Cowen and Company David Amsellem - Piper Jaffray & Co. Nicho...

146
Simply Wall StFeb 19

What Kind Of Shareholder Appears On The Revance Therapeutics, Inc.’s (NASDAQ:RVNC) Shareholder Register?

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! If you want to know who really controls Revance Therapeutics, Inc. (NASDAQ:RVNC), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. We also tend to see lower insider ownership in companies that were previously publicly owned. With a market capitali...

15

Earnings

-$1.12
-$0.98
-$0.85
-$0.71
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.